AbbVie Net Worth
AbbVie Net Worth Breakdown | ABBV |
AbbVie Net Worth Analysis
AbbVie's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including AbbVie's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of AbbVie's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform AbbVie's net worth analysis. One common approach is to calculate AbbVie's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares AbbVie's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing AbbVie's net worth. This approach calculates the present value of AbbVie's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of AbbVie's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate AbbVie's net worth. This involves comparing AbbVie's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into AbbVie's net worth relative to its peers.
To determine if AbbVie is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding AbbVie's net worth research are outlined below:
| AbbVie Inc generated a negative expected return over the last 90 days | |
| AbbVie Inc currently holds 59.38 B in liabilities with Debt to Equity (D/E) ratio of 4.37, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. AbbVie Inc has a current ratio of 0.91, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about AbbVie's use of debt, we should always consider it together with its cash and equity. | |
| AbbVie Inc has a strong financial position based on the latest SEC filings | |
| About 73.0% of AbbVie shares are held by institutions such as insurance companies | |
| Latest headline from fool.com: Got 1,500 3 Healthcare Stocks to Buy and Hold Forever |
AbbVie Quarterly Good Will |
|
AbbVie uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in AbbVie Inc. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to AbbVie's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 2nd of February 2024 Upcoming Quarterly Report | View | |
| 25th of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 2nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
AbbVie Target Price Consensus
AbbVie target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. AbbVie's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 29 | Strong Buy |
Most AbbVie analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand AbbVie stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of AbbVie Inc, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationAbbVie Target Price Projection
AbbVie's current and average target prices are 175.26 and 202.33, respectively. The current price of AbbVie is the price at which AbbVie Inc is currently trading. On the other hand, AbbVie's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
AbbVie Market Quote on 31st of January 2025
Target Price
Analyst Consensus On AbbVie Target Price
Know AbbVie's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as AbbVie is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading AbbVie Inc backward and forwards among themselves. AbbVie's institutional investor refers to the entity that pools money to purchase AbbVie's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Northern Trust Corp | 2024-09-30 | 19.5 M | Bank Of New York Mellon Corp | 2024-09-30 | 17.1 M | Capital World Investors | 2024-09-30 | 15.5 M | Legal & General Group Plc | 2024-09-30 | 15.2 M | Franklin Resources Inc | 2024-09-30 | 13.9 M | Ameriprise Financial Inc | 2024-09-30 | 13.8 M | Fmr Inc | 2024-09-30 | 13.6 M | Ubs Group Ag | 2024-09-30 | 11.5 M | Goldman Sachs Group Inc | 2024-09-30 | 10.7 M | Vanguard Group Inc | 2024-09-30 | 171.6 M | Blackrock Inc | 2024-09-30 | 136 M |
Follow AbbVie's market capitalization trends
The company currently falls under 'Mega-Cap' category with a current market capitalization of 310.4 B.Market Cap |
|
Project AbbVie's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.12 | 0.11 | |
| Return On Capital Employed | 0.15 | 0.22 | |
| Return On Assets | 0.04 | 0.04 | |
| Return On Equity | 0.54 | 0.65 |
When accessing AbbVie's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures AbbVie's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of AbbVie's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in AbbVie's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of AbbVie Inc. Check AbbVie's Beneish M Score to see the likelihood of AbbVie's management manipulating its earnings.
Evaluate AbbVie's management efficiency
AbbVie Inc has return on total asset (ROA) of 0.0772 % which means that it generated a profit of $0.0772 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.5641 %, meaning that it created $0.5641 on every $100 dollars invested by stockholders. AbbVie's management efficiency ratios could be used to measure how well AbbVie manages its routine affairs as well as how well it operates its assets and liabilities. At this time, AbbVie's Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to climb to 0.65 in 2025, whereas Return On Tangible Assets are likely to drop 0.11 in 2025. At this time, AbbVie's Non Current Assets Total are fairly stable compared to the past year. Other Assets is likely to climb to about 5.8 B in 2025, whereas Other Current Assets are likely to drop slightly above 3.5 B in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 5.29 | 3.02 | |
| Tangible Book Value Per Share | (50.41) | (52.93) | |
| Enterprise Value Over EBITDA | 16.67 | 10.02 | |
| Price Book Value Ratio | 30.41 | 17.20 | |
| Enterprise Value Multiple | 16.67 | 10.02 | |
| Price Fair Value | 30.41 | 17.20 | |
| Enterprise Value | 57.3 B | 50.9 B |
AbbVie's management has consistently demonstrated strong leadership, driving both financial growth and operational excellence. By analyzing current market trends and future growth opportunities, we assess the stock's true value and potential for investors.
Enterprise Value Revenue 6.7382 | Revenue | Quarterly Revenue Growth 0.038 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific AbbVie insiders, such as employees or executives, is commonly permitted as long as it does not rely on AbbVie's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases AbbVie insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Richard Gonzalez over a month ago Disposition of 87050 shares by Richard Gonzalez of AbbVie at 61.36 subject to Rule 16b-3 | ||
Timothy Richmond over a month ago Disposition of 30288 shares by Timothy Richmond of AbbVie at 177.71 subject to Rule 16b-3 | ||
Robert Alpern over six months ago Acquisition by Robert Alpern of tradable shares of AbbVie at 171.52 subject to Rule 16b-3 | ||
Edward Rapp over six months ago Acquisition by Edward Rapp of 212 shares of AbbVie at 182.1 subject to Rule 16b-3 | ||
Carrie Strom over a year ago Payment of 2876 shares by Carrie Strom of AbbVie subject to Rule 16b-3 |
AbbVie Corporate Filings
8K | 10th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 3rd of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 4th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
| 14th of August 2024 Other Reports | ViewVerify |
AbbVie Earnings Estimation Breakdown
The calculation of AbbVie's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of AbbVie is estimated to be 2.597625 with the future projection ranging from a low of 2.5016 to a high of 2.915. Please be aware that this consensus of annual earnings estimates for AbbVie Inc is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
2.50 Lowest | Expected EPS | 2.92 Highest |
AbbVie Earnings Projection Consensus
Suppose the current estimates of AbbVie's value are higher than the current market price of the AbbVie stock. In this case, investors may conclude that AbbVie is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and AbbVie's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 28 | 97.83% | 3.0 | 2.597625 | 2.86 |
AbbVie Earnings History
Earnings estimate consensus by AbbVie Inc analysts from Wall Street is used by the market to judge AbbVie's stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only AbbVie's upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.AbbVie Quarterly Gross Profit |
|
AbbVie Earnings per Share Projection vs Actual
Actual Earning per Share of AbbVie refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering AbbVie Inc predict the company's earnings will be in the future. The higher the earnings per share of AbbVie, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.AbbVie Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as AbbVie, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of AbbVie should always be considered in relation to other companies to make a more educated investment decision.AbbVie Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact AbbVie's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-10-30 | 2024-09-30 | 2.92 | 3.0 | 0.08 | 2 | ||
2024-07-25 | 2024-06-30 | 2.57 | 2.65 | 0.08 | 3 | ||
2024-04-26 | 2024-03-31 | 2.23 | 2.31 | 0.08 | 3 | ||
2024-02-02 | 2023-12-31 | 2.77 | 2.79 | 0.02 | 0 | ||
2023-10-27 | 2023-09-30 | 2.86 | 2.95 | 0.09 | 3 | ||
2023-07-27 | 2023-06-30 | 2.81 | 2.91 | 0.1 | 3 | ||
2023-04-27 | 2023-03-31 | 2.46 | 2.46 | 0.0 | 0 | ||
2023-02-09 | 2022-12-31 | 3.56 | 3.6 | 0.04 | 1 | ||
2022-10-28 | 2022-09-30 | 3.57 | 3.66 | 0.09 | 2 | ||
2022-07-29 | 2022-06-30 | 3.31 | 3.37 | 0.06 | 1 | ||
2022-04-29 | 2022-03-31 | 3.14 | 3.24 | 0.1 | 3 | ||
2022-02-02 | 2021-12-31 | 3.29 | 3.31 | 0.02 | 0 | ||
2021-10-29 | 2021-09-30 | 3.22 | 3.33 | 0.11 | 3 | ||
2021-07-30 | 2021-06-30 | 3.09 | 3.09 | 0.0 | 0 | ||
2021-04-30 | 2021-03-31 | 2.83 | 2.95 | 0.12 | 4 | ||
2021-02-03 | 2020-12-31 | 2.85 | 2.92 | 0.07 | 2 | ||
2020-10-30 | 2020-09-30 | 2.77 | 2.83 | 0.06 | 2 | ||
2020-07-31 | 2020-06-30 | 2.19 | 2.34 | 0.15 | 6 | ||
2020-05-01 | 2020-03-31 | 2.25 | 2.42 | 0.17 | 7 | ||
2020-02-07 | 2019-12-31 | 2.19 | 2.21 | 0.02 | 0 | ||
2019-11-01 | 2019-09-30 | 2.3 | 2.33 | 0.03 | 1 | ||
2019-07-26 | 2019-06-30 | 2.21 | 2.26 | 0.05 | 2 | ||
2019-04-25 | 2019-03-31 | 2.05 | 2.14 | 0.09 | 4 | ||
2019-01-25 | 2018-12-31 | 1.94 | 1.9 | -0.04 | 2 | ||
2018-11-02 | 2018-09-30 | 2.02 | 2.14 | 0.12 | 5 | ||
2018-07-27 | 2018-06-30 | 1.97 | 2.0 | 0.03 | 1 | ||
2018-04-26 | 2018-03-31 | 1.79 | 1.87 | 0.08 | 4 | ||
2018-01-26 | 2017-12-31 | 1.44 | 1.48 | 0.04 | 2 | ||
2017-10-27 | 2017-09-30 | 1.38 | 1.41 | 0.03 | 2 | ||
2017-07-28 | 2017-06-30 | 1.4 | 1.42 | 0.02 | 1 | ||
2017-04-27 | 2017-03-31 | 1.26 | 1.28 | 0.02 | 1 | ||
2017-01-27 | 2016-12-31 | 1.2 | 1.2 | 0.0 | 0 | ||
2016-10-28 | 2016-09-30 | 1.2 | 1.21 | 0.01 | 0 | ||
2016-07-29 | 2016-06-30 | 1.2 | 1.26 | 0.06 | 5 | ||
2016-04-28 | 2016-03-31 | 1.13 | 1.15 | 0.02 | 1 | ||
2016-01-29 | 2015-12-31 | 1.12 | 1.13 | 0.01 | 0 | ||
2015-10-30 | 2015-09-30 | 1.08 | 1.13 | 0.05 | 4 | ||
2015-07-24 | 2015-06-30 | 1.06 | 1.08 | 0.02 | 1 | ||
2015-04-23 | 2015-03-31 | 0.85 | 0.94 | 0.09 | 10 | ||
2015-01-30 | 2014-12-31 | 0.86 | 0.89 | 0.03 | 3 | ||
2014-10-31 | 2014-09-30 | 0.77 | 0.89 | 0.12 | 15 | ||
2014-07-25 | 2014-06-30 | 0.76 | 0.82 | 0.06 | 7 | ||
2014-04-25 | 2014-03-31 | 0.68 | 0.71 | 0.03 | 4 | ||
2014-01-31 | 2013-12-31 | 0.82 | 0.82 | 0.0 | 0 | ||
2013-10-25 | 2013-09-30 | 0.78 | 0.82 | 0.04 | 5 | ||
2013-07-26 | 2013-06-30 | 0.79 | 0.82 | 0.03 | 3 | ||
2013-04-26 | 2013-03-31 | 0.67 | 0.68 | 0.01 | 1 | ||
2013-01-23 | 2012-12-31 | 0.99 | 0.9761 | -0.0139 | 1 |
AbbVie Corporate Directors
| Brett Hart | Independent Director | Profile | |
| Roxanne Austin | Independent Director | Profile | |
| Edward Rapp | Independent Director | Profile | |
| Frederick Waddell | Independent Director | Profile |
Already Invested in AbbVie Inc?
The danger of trading AbbVie Inc is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of AbbVie is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than AbbVie. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile AbbVie Inc is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for AbbVie Stock Analysis
When running AbbVie's price analysis, check to measure AbbVie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AbbVie is operating at the current time. Most of AbbVie's value examination focuses on studying past and present price action to predict the probability of AbbVie's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AbbVie's price. Additionally, you may evaluate how the addition of AbbVie to your portfolios can decrease your overall portfolio volatility.